The hearing at the U.S. Patent and Trademark Office regarding two patents for clustered, regularly-interspaced short palindromic repeats (CRISPR) is a pivotal moment for the intellectual properties associated with the technology, but Bob Underwood, a partner at the Chicago office of McDermott Will & Emery, told BioWorld Today that prognostication on the outcome is a dicey exercise.